23 December 2024 - Glaukos today announced the submission of its new drug application to the US FDA for Epioxa, its next generation corneal cross-linking iLink therapy for the treatment of keratoconus, a progressive, sight threatening corneal disease.

The new drug application submission includes data from two Phase 3 pivotal trials of Epioxa, which both successfully achieved the pre-specified primary efficacy endpoints and demonstrated favourable tolerability and safety profiles.

Read Glaukos press release